Actively Recruiting

Age: 18Years - 100Years
All Genders
ID06473415

Electroencephalography and Sleep Quality With Lormetazepam in the Intensive Care Unit

Led by Charite University, Berlin, Germany · Updated on 2024-06-26

50

Participants Needed

1

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to understand how continuous infusion of lormetazepam affects brain activity, sleep quality, and sedation depth in critically ill patients in an intensive care unit (ICU). The study focuses on patients who require sedation and are expected to receive lormetazepam continuously for at least 24 hours. It explores specific EEG patterns related to sleep stages and sedation effects to improve sedation monitoring and potentially reduce complications like delirium and cognitive damage. Participants will receive lormetazepam infusion as determined by their ICU physician. Brain activity will be monitored using up to three 24-hour EEG recordings with the X8 Sleep Profiler RTA device, starting at least two hours after beginning lormetazepam infusion. This observational pilot study does not have a comparison group but includes an interim analysis after 15 patients to assess the measurement approach and possibly adjust study procedures. During the study, patients will undergo EEG monitoring to record various sleep and brain activity parameters including REM sleep, slow wave sleep, gamma oscillations, and sedation depth. Additional clinical data such as delirium incidence, sedation scales, ventilation duration, and organ function scores will also be collected. The study aims to enroll 50 ICU patients expected to require intensive care for at least 48 hours and continuous lormetazepam infusion for 24 hours or more. The total participation spans several days with repeated EEG and clinical assessments to evaluate sedation and sleep quality in this critical setting.

CONDITIONS

Brief Title

Electroencephalography and Sleep Quality With Lormetazepam in the Intensive Care Unit

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient capable of giving consent or having a legal guardian/authorized representative/spouse available
  • Expected continuous lormetazepam therapy of at least 24 hours
  • Male and female patients aged 18 years or older
  • Expected intensive care treatment duration of 48 hours or longer
  • Receiving mechanical ventilation (invasive, non-invasive, or nasal high-flow for more than 6 hours)
Not Eligible

You will not qualify if you...

  • Laboratory evidence of sedative or opiate intoxication
  • Active alcohol abuse
  • Brain surgery or cranial malformation
  • History of sleep-related movement disorder such as symptomatic restless legs syndrome
  • Allergy to electrode contact material
  • History of severe cognitive impairment following a stroke
  • Undergoing therapeutic hypothermia after cardiopulmonary resuscitation
  • Lack of consent for pseudonymized data storage and sharing
  • Patient housed in an institution by court or official order
  • History of sleep-related breathing disorder
  • Suspicion of hypoxic brain damage including intracranial hemorrhages
  • Suspicion of increased intracranial pressure
  • Existing power of attorney or patient will excluding study participation
  • Consent cannot be obtained in a timely manner
  • Survival probability less than 24 hours
  • Diagnosis of narcolepsy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Immediately after ICU admission and reevaluated daily

Participants are screened for eligibility to participate in the trial.

Daily screening during ICU stay

Monitoring

Duration - Approximately 3 days during ICU stay

Participants receiving continuous lormetazepam infusion undergo episodic EEG recordings to assess sleep quality and brain activity patterns.

Up to 3 EEG measurement sessions over 24 hours each

Trial Site Locations

Total: 1 location

1

Charité - Universitätsmedizin Berlin

Mitte, State of Berlin, Germany, 10117

Actively Recruiting

Loading map...

Research Team

A

Alawi Luetz, Prof.Dr.med

L

Laura Hancke

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

PROTECT-ICU: Impact of an Educational Intervention on the Im...

Post Intensive Care Syndrome (PICS)

Actively Recruiting

2 locations

Establishment of a Multi-Center Big Data System for Severe I...

Critical Illness

Actively Recruiting

1 location

A Multi-Modal Combination Intervention to Promote Cognitive ...

Critical Illness

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here